Gastrointestinal Carcinoid Tumor
21
0
0
15
Key Insights
Highlights
Success Rate
79% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
19.0%
4 terminated out of 21 trials
78.9%
-7.6% vs benchmark
0%
0 trials in Phase 3/4
27%
4 of 15 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 15 completed trials
Clinical Trials (21)
AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors
Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors
Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
Doxorubicin Beads in Treating Patients With Unresectable Liver Metastases From Neuroendocrine Tumors
Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal Cancer
Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors
Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery
Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors
Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer
Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features
Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors
Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors
Oxaliplatin Plus Irinotecan in Treating Patients With Metastatic Gastrointestinal Cancer
Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors
Fluorouracil Plus Interferon Alfa in Treating Patients With Advanced Metastatic Carcinoid Tumors
Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer
PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors
Endoscopic Placement of Metal Stent in Patients With Cancer-Related Bowel Obstruction
Endoscopic Placement of Metal Stents in Treating Patients With Cancer- Related Duodenal Obstruction